Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
- Oral presentation of intravenous VRDN-001 preclinical and Phase 1/2 clinical data – - Poster presentations of subcutaneous VRDN-003 preclinical data – - Subcutaneous program selection for...
San Francisco United States Neither The Company Viridian Therapeutics Inc Antagonist Properties Exchange Commission
Source: marketscreener.com